Combigene Ab Stock Profit Margin

In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.

Based on the latest financial disclosure, Combigene AB has a Profit Margin of 0.5858%. This is 105.23% lower than that of the Healthcare sector and 102.54% lower than that of the Biotechnology industry. The profit margin for all Sweden stocks is 146.13% lower than that of the firm.

The Macroaxis Fundamental Analysis modules help investors analyze Combigene AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Combigene using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Combigene AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

When running Combigene's price analysis, check to measure Combigene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Combigene is operating at the current time. Most of Combigene's value examination focuses on studying past and present price action to predict the probability of Combigene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Combigene's price. Additionally, you may evaluate how the addition of Combigene to your portfolios can decrease your overall portfolio volatility.